BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination

Activation of farnesoid X receptor (FXR) by obeticholic acid (OCA) reduces hepatic inflammation and fibrosis in patients with primary biliary cholangitis (PBC), a life-threatening cholestatic liver failure. Inhibition of bromodomain-containing protein 4 (BRD4) also has antiinflammatory, antifibrotic...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Hyunkyung, Chen, Jinjing, Hu, Xiangming, Sun, Hao, Wu, Shwu-Yuan, Chiang, Cheng-Ming, Kemper, Byron, Chen, Lin-Feng, Kemper, Jongsook Kim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821603/
https://www.ncbi.nlm.nih.gov/pubmed/33290278
http://dx.doi.org/10.1172/jci.insight.141640

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821603/
https://www.ncbi.nlm.nih.gov/pubmed/33290278
http://dx.doi.org/10.1172/jci.insight.141640

Ejemplares similares